Docoh
Loading...
Sign up Log in

INBP Integrated Biopharma

Integrated BioPharma, Inc. engages in the manufacture, distribution, marketing, and sale of vitamins, nutritional supplements and herbal products. It operates through the following segments: Contract Manufacturing, Branded Proprietary Products, and Other Nutraceutical Businesses. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers. The Branded Proprietary Products segment distributes nutritional products through mass market, grocery, drug and vitamin retailers. The Other Nutraceutical Businesses segment sells private label MDC products, as well as AgroLabs products. The company was founded by E. Gerald Kay in March 1980 and is headquartered in Hillside, NJ.

Company profile

Ticker
INBP
Exchange
NASDAQ
Website
www.ibiopharma.com
CEO
Riva Kay Sheppard / Christina Kay
Employees
Incorporated
Delaware
Location
New Jersey
Fiscal year end
Jun 30
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...
Former names
CHEM INTERNATIONAL INC, INTEGRATED HEALTH TECHNOLOGIES INC
SEC CIK
0001016504
Corporate docs
IRS number
222407475

INBP stock data

(
)

News

Pro users get this 30m faster
Multiple Miners Make Their Way In for Q1 OTC Market Index Rebalancing
28 May 21
The indices that track trading on OTC Markets saw several changes occur in Q1. Here is a deeper look at the companies that were added and removed in each of the market’s major indices that were rebalanced for the quarter:

Press releases

Pro users get this 30m faster
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021
13 May 21
HILLSIDE, NJ / ACCESSWIRE / May 13, 2021 / Integrated BioPharma, Inc. ((OTCQX: INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2021.

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 May 21
31 Jul 21
30 Jul 22

Financial summary

Financial statements Chart INBP financial data
Quarter (USD)
 Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Jun 20 Jun 19 Jun 18 Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 105K 105K 105K 105K 105K 105K
Cash burn (monthly) (positive/no burn) 38.33K (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a 153.94K n/a n/a n/a n/a
Cash remaining n/a -48.94K n/a n/a n/a n/a
Runway (months of cash) n/a -1.3 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Recent insider trades

INBP insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
4 Nov 20 Dina Masi Stock Option Common Stock Grant Aquire A No No 0.65 100,000 65K 100,000
4 Nov 20 Eric J Friedman Stock Option Common Stock Grant Aquire A No No 0.65 50,000 32.5K 50,000
4 Nov 20 Christina Kay Stock Option Common Stock Grant Aquire A No No 0.65 100,000 65K 100,000
4 Nov 20 Sheppard Riva Stock Option Common Stock Grant Aquire A No No 0.65 100,000 65K 100,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: affiliated, bottle, fuel, key, meet, reapplied, refinery, shipping, transportation, upgraded
Removed: remained
From filing 10-Q 2021 Q3

Financial reports

View all
10-Q
2021 Q3
Quarterly report
13 May 21
10-Q
2021 Q2
Quarterly report
12 Feb 21
10-Q
2021 Q1
Quarterly report
12 Nov 20
10-K
2020 FY
Annual report
23 Sep 20
10-Q
2020 Q3
Quarterly report
13 May 20
10-Q
2020 Q2
Quarterly report
12 Feb 20
10-Q
2020 Q1
Quarterly report
13 Nov 19
10-K
2019 FY
Annual report
29 Aug 19
10-Q
2019 Q3
Quarterly report
15 May 19
10-Q
2019 Q2
Quarterly report
12 Feb 19

Current reports

View all
8-K
Termination of a Material Definitive Agreement
7 Jul 21
8-K
Results of Operations and Financial Condition
13 May 21
8-K
Integrated BioPharma Announces Launch of Investors Website
8 Apr 21
8-K
Results of Operations and Financial Condition
12 Feb 21
8-K
Integrated BioPharma Announces Upgrade to OTCQX
22 Jan 21
8-K
Submission of Matters to a Vote of Security Holders
30 Nov 20
8-K
Results of Operations and Financial Condition
12 Nov 20
8-K
Departure of Directors or Certain Officers
9 Nov 20
8-K
Financial Statements and Exhibits
24 Sep 20
8-K
Results of Operations and Financial Condition
13 May 20

Registration and prospectus

View all
S-8
Registration of securities for employees
28 Dec 18
D
$5.35M in debt / securities to be acquired, sold $5.35M, 1 investor
10 Jul 12
25
Voluntary exchange delisting
12 Apr 09
424B3
Prospectus supplement
5 May 08
S-3/A
Shelf registration (amended)
28 Apr 08
S-3/A
Shelf registration (amended)
16 Apr 08
S-3/A
Shelf registration (amended)
15 Apr 08
S-3
Shelf registration
20 Mar 08
REGDEX
Notice of sale of securities
6 Mar 08
RW
Registration withdrawal request
22 Aug 07

Proxies

View all
DEF 14A
Definitive proxy
28 Oct 20
DEF 14A
Definitive proxy
28 Oct 19
DEF 14A
Definitive proxy
29 Oct 18
DEF 14A
Definitive proxy
26 Oct 17
DEF 14A
Definitive proxy
27 Oct 16
DEF 14A
Definitive proxy
25 Oct 15
DEF 14A
Definitive proxy
27 Oct 14
DEFA14A
Additional proxy soliciting materials
5 Nov 13
DEF 14A
Definitive proxy
27 Oct 13
DEFA14A
Additional proxy soliciting materials
4 Nov 12

Other

View all
UPLOAD
Letter from SEC
3 Aug 08
EFFECT
Notice of effectiveness
1 May 08
CORRESP
Correspondence with SEC
29 Apr 08
UPLOAD
Letter from SEC
21 Apr 08
UPLOAD
Letter from SEC
26 Mar 08
UPLOAD
Letter from SEC
26 Mar 08
UPLOAD
Letter from SEC
12 Mar 08
EFFECT
Notice of effectiveness
10 Jul 07
CORRESP
Correspondence with SEC
9 Feb 05
UPLOAD
Letter from SEC
17 Jan 05

Ownership

View all
4
INTEGRATED BIOPHARMA / CARL DESANTIS ownership change
20 Nov 20
4
INTEGRATED BIOPHARMA / E GERALD KAY ownership change
20 Nov 20
4
INTEGRATED BIOPHARMA / Robert Canarick ownership change
20 Nov 20
4
INTEGRATED BIOPHARMA / William H. Milmoe ownership change
20 Nov 20
4
INTEGRATED BIOPHARMA / SHEPPARD RIVA ownership change
20 Nov 20
4
INTEGRATED BIOPHARMA / CHRISTINA KAY ownership change
20 Nov 20
4
INTEGRATED BIOPHARMA / ERIC J FRIEDMAN ownership change
20 Nov 20
4
INTEGRATED BIOPHARMA / Dina Masi ownership change
20 Nov 20
3
INTEGRATED BIOPHARMA / ERIC J FRIEDMAN ownership change
17 Nov 20
4
INTEGRATED BIOPHARMA / CARL DESANTIS ownership change
29 May 19

Reddit threads

Pro users get this 30m faster